ARB Medication for Hypertension Management
For non-Black patients with hypertension, start with a low-dose ARB (or ACE inhibitor), titrate to full dose, then add a thiazide/thiazide-like diuretic if needed; for Black patients, start with a low-dose ARB combined with a dihydropyridine calcium channel blocker (DHP-CCB) or thiazide diuretic. 1
Initial Drug Selection
Non-Black Patients
- Start with low-dose ACE inhibitor or ARB as first-line monotherapy 1
- ARBs are preferred when ACE inhibitors cause intolerable cough, as they provide comparable blood pressure reduction with superior tolerability 2
- All ARBs demonstrate similar antihypertensive efficacy, with no clinically meaningful differences between agents 3, 4
Black Patients
- Begin with low-dose ARB combined with DHP-CCB or thiazide/thiazide-like diuretic 1
- Monotherapy with ARB alone is less effective in Black patients 1
Starting Dose and Titration Strategy
Dosing Approach
- Start at 1/4 to 1/2 of the manufacturer's maximum recommended dose, which achieves 60-80% of maximum blood pressure lowering effect 4
- Titrate to full dose before adding additional agents 1
- Doses above the maximum recommended provide no additional blood pressure reduction 4
Titration Timeline
- Review and adjust treatment every 2-4 weeks until blood pressure is controlled 5
- Target achievement within 3 months of initiating therapy 1
Sequential Treatment Algorithm
Step 1: Monotherapy
Step 2: Dose Escalation
- Increase to full-dose ARB before adding second agent 1
Step 3: Two-Drug Combination
- Add thiazide/thiazide-like diuretic (non-Black patients) 1
- Add diuretic or increase to full dose of initial combination (Black patients) 1
- Preferred combinations: ARB + DHP-CCB or ARB + thiazide 6
- Use fixed-dose single-pill combinations to improve adherence 6
Step 4: Three-Drug Combination
- ARB + DHP-CCB + thiazide/thiazide-like diuretic, preferably as single-pill combination 6
Step 5: Resistant Hypertension
- Add spironolactone as fourth-line agent 1
- Alternatives if spironolactone not tolerated: amiloride, doxazosin, eplerenone, clonidine, or beta-blocker 1
Blood Pressure Targets
Primary Targets
- Aim for systolic BP 120-129 mmHg if well tolerated 6
- Minimum acceptable target: <140/90 mmHg 1
- For high-risk patients or those with CVD: <130/80 mmHg 1
Special Populations
- Individualize targets for elderly patients based on frailty status 1
- Consider monotherapy in patients >80 years or frail 1
Monitoring Parameters
Blood Pressure Monitoring
- Confirm diagnosis with home BP monitoring (target <135/85 mmHg) or 24-hour ambulatory BP monitoring (target <130/80 mmHg) 1
- Reassess BP control monthly until target achieved 7
- Use validated automated upper arm cuff devices with appropriate cuff size 1
Laboratory Monitoring
- Monitor renal function and potassium levels when initiating or adjusting ARB therapy 8
- Check for albuminuria in high-risk patients, as elevated levels strongly indicate need for ARB therapy 9
Important Clinical Considerations
Compelling Indications for ARBs
- Chronic kidney disease with albuminuria 9
- Heart failure with reduced ejection fraction 7
- Post-myocardial infarction 7
- Diabetes mellitus 1
- ARBs demonstrate neutral metabolic effects compared to beta-blockers and diuretics 2
Contraindications and Precautions
- Never combine ARB with ACE inhibitor (dual RAS blockade not recommended) 6
- Monitor for hyperkalemia and declining renal function 8
- Adjust or discontinue if eGFR declines significantly 8
Timing of Administration
- Take medications at the most convenient time to establish habitual pattern and improve adherence 6
- Bedtime dosing may provide superior reduction in microalbuminuria compared to morning dosing in patients with morning hypertension 10